If Small Molecules Immunotherapy Comes, Can the Prime be Far Behind?
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
If Small Molecules Immunotherapy Comes, Can the Prime be Far Behind?
Authors
Keywords
Cancer immunotherapy, Small molecule inhibitors, Combination therapy, Tumor microenvironment
Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume -, Issue -, Pages 113356
Publisher
Elsevier BV
Online
2021-03-12
DOI
10.1016/j.ejmech.2021.113356
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Small molecule targeting of SHIP1 and SHIP2
- (2020) William G. Kerr et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and independent effects by CDK6-specific PROTACs
- (2020) Marco De Dominici et al. BLOOD
- Cellular Immunotherapy in Lymphoma: Beyond CART Cells
- (2020) Mahmoud R. Gaballa et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Zanubrutinib: First Approval
- (2020) Yahiya Y. Syed DRUGS
- Arginase inhibitor, Nω-hydroxy-L-norarginine, spontaneously releases biologically active NO-like molecule: Limitations for research applications
- (2020) Tony Y. Momma et al. FREE RADICAL BIOLOGY AND MEDICINE
- A phase I study to evaluate the safety and tolerability of AB680 combination therapy in participants with gastrointestinal malignancies.
- (2020) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase Ib/II, open-label, platform study evaluating the efficacy and safety of AB928-based treatment combinations in participants with metastatic castrate-resistant prostate cancer.
- (2020) David R. Wise et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
- (2020) Daixi Ren et al. Molecular Cancer
- Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs
- (2020) Niall A. Anderson et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Tirabrutinib: First Approval
- (2020) Sohita Dhillon DRUGS
- Development of small molecule inhibitors targeting TGF-β ligand and receptor: Structures, mechanism, preclinical studies and clinical usage
- (2020) Hao Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes
- (2020) Cindy Patinote et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Gasdermin E suppresses tumour growth by activating anti-tumour immunity
- (2020) Zhibin Zhang et al. NATURE
- A Chemical Switch System to Modulate Chimeric Antigen Receptor T Cell Activity through Proteolysis-Targeting Chimaera Technology
- (2020) So Myoung Lee et al. ACS Synthetic Biology
- Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data
- (2020) Krista Isaac et al. Cancer Management and Research
- Small molecules targeting the innate immune cGAS‒STING‒TBK1 signaling pathway
- (2020) Chunyong Ding et al. Acta Pharmaceutica Sinica B
- Mechanisms of B Cell Receptor Activation and Responses to B Cell Receptor Inhibitors in B Cell Malignancies
- (2020) Dimitar G. Efremov et al. Cancers
- The adenosine pathway in immuno-oncology
- (2020) Bertrand Allard et al. Nature Reviews Clinical Oncology
- Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders
- (2020) Kai Tang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy
- (2020) Leila Motedayen Aval et al. Journal of Clinical Medicine
- Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy
- (2020) Yufei Wang et al. Cancers
- Correction to “Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein”
- (2020) Mingliang Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy
- (2019) Daniel Shae et al. Nature Nanotechnology
- Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase
- (2019) Blake E. Smith et al. Nature Communications
- Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy
- (2019) Jun Wang et al. NATURE MEDICINE
- Degradation of Bruton’s tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas
- (2019) Yonghui Sun et al. LEUKEMIA
- Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors
- (2019) Jeffrey T. Bagdanoff et al. JOURNAL OF MEDICINAL CHEMISTRY
- Bruton’s tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018)
- (2019) Yifan Feng et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- FDA Approval Summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors
- (2019) Leigh Marcus et al. CLINICAL CANCER RESEARCH
- Transforming Growth Factor-β Signaling in Immunity and Cancer
- (2019) Eduard Batlle et al. IMMUNITY
- A phase I/Ib multicenter study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent, in combination with CPI-444, and in combination with pembrolizumab in adult patients with advanced cancers.
- (2019) Mehrdad Mobasher et al. JOURNAL OF CLINICAL ONCOLOGY
- Mitotic regulators and the SHP2-MAPK pathway promote IR endocytosis and feedback regulation of insulin signaling
- (2019) Eunhee Choi et al. Nature Communications
- Discovery and Mechanistic Study of a Novel Human-Stimulator-of-Interferon-Genes Agonist
- (2019) Xiaohui Zhang et al. ACS Infectious Diseases
- STING pathway agonism as a cancer therapeutic
- (2019) Blake A. Flood et al. IMMUNOLOGICAL REVIEWS
- Design, Synthesis, Evaluation, and Structural Studies of C2-Symmetric Small Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein–Protein Interaction
- (2019) Subhadwip Basu et al. JOURNAL OF MEDICINAL CHEMISTRY
- PROTACs– a game-changing technology
- (2019) Markella Konstantinidou et al. Expert Opinion on Drug Discovery
- TGF-β signaling controls Foxp3 methylation and T reg cell differentiation by modulating Uhrf1 activity
- (2019) Xiang Sun et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies
- (2019) Stefanie R. Mullins et al. Journal for ImmunoTherapy of Cancer
- STING Activation and its Application in Immuno-Oncology
- (2019) Yiqian Lian et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Latest Advances in Small Molecule TLR 7/8 Agonist Drug Research
- (2019) David C. McGowan CURRENT TOPICS IN MEDICINAL CHEMISTRY
- STING: a master regulator in the cancer-immunity cycle
- (2019) Yuanyuan Zhu et al. Molecular Cancer
- The cGAS-STING pathway is a therapeutic target in a preclinical model of hepatocellular carcinoma
- (2019) Martin K. Thomsen et al. ONCOGENE
- Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity
- (2019) Kelsey E. Sivick et al. Cell Reports
- A Perspective on the Development of TGF-β Inhibitors for Cancer Treatment
- (2019) Huynh et al. Biomolecules
- Targeting SHP2 as a promising strategy for cancer immunotherapy
- (2019) Qianqian Liu et al. PHARMACOLOGICAL RESEARCH
- The Cytosolic DNA-Sensing cGAS–STING Pathway in Cancer
- (2019) John Kwon et al. Cancer Discovery
- Dual Allosteric Inhibition of SHP2 Phosphatase
- (2018) Michelle Fodor et al. ACS Chemical Biology
- Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated Degradation
- (2018) Alexandru D. Buhimschi et al. BIOCHEMISTRY
- TIGIT immune checkpoint blockade restores CD8+T cell immunity against multiple myeloma
- (2018) Camille Guillerey et al. BLOOD
- PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies
- (2018) Yonghui Sun et al. CELL RESEARCH
- Activation of Adenylyl Cyclase Causes Stimulation of Adenosine Receptors
- (2018) Thomas Pleli et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review
- (2018) Chengyuan Liang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Metabolic therapy with PEG-arginase induces a sustained complete remission in immunotherapy-resistant melanoma
- (2018) Carmela De Santo et al. Journal of Hematology & Oncology
- Functional Anti-TIGIT Antibodies Regulate Development of Autoimmunity and Antitumor Immunity
- (2018) Karen O. Dixon et al. JOURNAL OF IMMUNOLOGY
- Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
- (2018) Qing Zhang et al. NATURE IMMUNOLOGY
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacology of Adenosine Receptors: The State of the Art
- (2018) Pier Andrea Borea et al. PHYSIOLOGICAL REVIEWS
- TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy
- (2018) Christopher B. Rodell et al. Nature Biomedical Engineering
- Design and synthesis of tetrahydropyridopyrimidine based Toll-Like Receptor (TLR) 7/8 dual agonists
- (2018) David C. McGowan et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer
- (2018) Abdi Ghaffari et al. BRITISH JOURNAL OF CANCER
- Recent advances in small molecule based cancer immunotherapy
- (2018) Binbin Cheng et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Epidermal mast cells in Bowenoid papulosis during topical imiquimod therapy
- (2018) Takako Miura et al. JOURNAL OF DERMATOLOGY
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti–PD-(L)1 and Anti–CTLA-4 in Preclinical Models
- (2018) Stephen B. Willingham et al. Cancer Immunology Research
- A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily
- (2018) Anil Korkut et al. Cell Systems
- SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
- (2018) Mingxia Zhao et al. Acta Pharmaceutica Sinica B
- Vitamin K1 cream significantly reduces incidence and severity of cetuximab-related acneiform skin rash in women: a post hoc analysis of the EVITA trial
- (2018) M R Gaiser et al. ANNALS OF ONCOLOGY
- Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy?
- (2018) Tingkai Chen et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers
- (2018) Lisa Seitz et al. INVESTIGATIONAL NEW DRUGS
- The Next Generation of Immunotherapy for Cancer: Small Molecules Could Make Big Waves
- (2018) William G. Kerr et al. JOURNAL OF IMMUNOLOGY
- Recent clinical trends in Toll-like receptor targeting therapeutics
- (2018) Muhammad Ayaz Anwar et al. MEDICINAL RESEARCH REVIEWS
- Design of amidobenzimidazole STING receptor agonists with systemic activity
- (2018) Joshi M. Ramanjulu et al. NATURE
- Specific MHC-I Peptides Are Induced Using PROTACs
- (2018) Stephanie M. Jensen et al. Frontiers in Immunology
- The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets
- (2017) Bertrand Allard et al. IMMUNOLOGICAL REVIEWS
- Extracellular 5′-nucleotidase (CD73) promotes human breast cancer cells growth through AKT/GSK-3β/β-catenin/cyclinD1 signaling pathway
- (2017) Jiangang Yu et al. INTERNATIONAL JOURNAL OF CANCER
- Shp2 Plays a Critical Role in IL-6-Induced EMT in Breast Cancer Cells
- (2017) Xuan Sun et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy
- (2017) Paul A. Beavis et al. JOURNAL OF CLINICAL INVESTIGATION
- Ibrutinib treatment improves T cell number and function in CLL patients
- (2017) Meixiao Long et al. JOURNAL OF CLINICAL INVESTIGATION
- Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors
- (2017) Jennifer Sheng et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Synthesis and adenosine receptors binding studies of new fluorinated analogues of pyrido[2,3-d]pyrimidines and quinazolines
- (2017) Balakumar Chandrasekaran et al. MEDICINAL CHEMISTRY RESEARCH
- A STING-activating nanovaccine for cancer immunotherapy
- (2017) Min Luo et al. Nature Nanotechnology
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
- (2017) Enfu Hui et al. SCIENCE
- Dual enhancement of T and NK cell function by pulsatile inhibition of SHIP1 improves antitumor immunity and survival
- (2017) Matthew Gumbleton et al. Science Signaling
- Evolutionary Origins of cGAS-STING Signaling
- (2017) Shally R. Margolis et al. TRENDS IN IMMUNOLOGY
- SHP2 overexpression enhances the invasion and metastasis of ovarian cancer in vitro and in vivo
- (2017) Zhongqian Hu et al. OncoTargets and Therapy
- Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability
- (2017) Junhun Cho et al. Oncotarget
- Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PDL1 blockade
- (2017) Jie Bai et al. Oncotarget
- Dual enhancement of T and NK cell function by pulsatile inhibition of SHIP1 improves antitumor immunity and survival
- (2017) Matthew Gumbleton et al. Science Signaling
- Arginine Metabolism in Myeloid Cells Shapes Innate and Adaptive Immunity
- (2017) Paulo C. Rodriguez et al. Frontiers in Immunology
- Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment
- (2017) Susanne M. Steggerda et al. Journal for ImmunoTherapy of Cancer
- Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment
- (2016) Andrew Stiff et al. CANCER RESEARCH
- CD73–adenosine: a next-generation target in immuno-oncology
- (2016) David Allard et al. Immunotherapy
- Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor
- (2016) Jorge Garcia Fortanet et al. JOURNAL OF MEDICINAL CHEMISTRY
- A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma
- (2016) Alba A. Brandes et al. NEURO-ONCOLOGY
- Adenosine as a Multi-Signalling Guardian Angel in Human Diseases: When, Where and How Does it Exert its Protective Effects?
- (2016) Pier Andrea Borea et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- CD73 as a novel marker for poor prognosis of oral squamous cell carcinoma
- (2016) ZHEN-HU REN et al. Oncology Letters
- High expression of CD39 in gastric cancer reduces patient outcome following radical resection
- (2016) Xiao-Yan Cai et al. Oncology Letters
- Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)
- (2016) Krzysztof M. Zak et al. Oncotarget
- T lymphocyte SHP2-deficiency triggers anti-tumor immunity to inhibit colitis-associated cancer in mice
- (2016) Wen Liu et al. Oncotarget
- Plasticity between Epithelial and Mesenchymal States Unlinks EMT from Metastasis-Enhancing Stem Cell Capacity
- (2016) Evelyne Beerling et al. Cell Reports
- Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade
- (2016) E. Moore et al. Cancer Immunology Research
- Motolimod effectively drives immune activation in advanced cancer patients
- (2016) Gregory N. Dietsch OncoImmunology
- CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer
- (2015) B. G. Leclerc et al. CLINICAL CANCER RESEARCH
- Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib - Findings from an Investigator-Initiated Phase II Study
- (2015) C. U. Niemann et al. CLINICAL CANCER RESEARCH
- CD73 Predicts Favorable Prognosis in Patients with Nonmuscle-Invasive Urothelial Bladder Cancer
- (2015) Marian S. Wettstein et al. DISEASE MARKERS
- Cancer immunotherapy: harnessing the immune system to battle cancer
- (2015) Yiping Yang JOURNAL OF CLINICAL INVESTIGATION
- Effect of TLR Agonists on the Differentiation and Function of Human Monocytic Myeloid-Derived Suppressor Cells
- (2015) Jing Wang et al. JOURNAL OF IMMUNOLOGY
- α,β-Methylene-ADP (AOPCP) Derivatives and Analogues: Development of Potent and Selective ecto-5′-Nucleotidase (CD73) Inhibitors
- (2015) Sanjay Bhattarai et al. JOURNAL OF MEDICINAL CHEMISTRY
- Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance
- (2015) Kari R. Fischer et al. NATURE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of CD73 on human colorectal cancer cell growth in vivo and in vitro
- (2015) RUIMIN WU et al. ONCOLOGY REPORTS
- Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK
- (2015) Idit Sagiv-Barfi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immunological mechanisms of the antitumor effects of supplemental oxygenation
- (2015) Stephen M. Hatfield et al. Science Translational Medicine
- STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade
- (2015) Juan Fu et al. Science Translational Medicine
- Coordinate Expansion of Murine Hematopoietic and Mesenchymal Stem Cell Compartments by SHIPi
- (2015) R. Brooks et al. STEM CELLS
- Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
- (2015) Krzysztof M. Zak et al. STRUCTURE
- Arginase: an old enzyme with new tricks
- (2015) Ruth B. Caldwell et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Anticancer effect of adenosine on gastric cancerviadiverse signaling pathways
- (2015) Ayako Tsuchiya WORLD JOURNAL OF GASTROENTEROLOGY
- Structural insights into the reaction mechanism of S-adenosyl-L-homocysteine hydrolase
- (2015) Yoshio Kusakabe et al. Scientific Reports
- Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity
- (2015) Leticia Corrales et al. Cell Reports
- SHIPi Enhances Autologous and Allogeneic Hematopoietic Stem Cell Transplantation
- (2015) Sandra Fernandes et al. EBioMedicine
- A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy
- (2015) Robert D. Leone et al. Computational and Structural Biotechnology Journal
- Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
- (2015) Luisa Carbognin et al. PLoS One
- Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects
- (2015) Taolin Yi et al. Oncotarget
- PD-1/SHP-2 Inhibits Tc1/Th1 Phenotypic Responses and the Activation of T Cells in the Tumor Microenvironment
- (2014) J. Li et al. CANCER RESEARCH
- Antimetastatic Effects of Blocking PD-1 and the Adenosine A2A Receptor
- (2014) D. Mittal et al. CANCER RESEARCH
- SHP2E76K mutant promotes lung tumorigenesis in transgenic mice
- (2014) Valentina E. Schneeberger et al. CARCINOGENESIS
- Impaired T-cell survival promotes mucosal inflammatory disease in SHIP1-deficient mice
- (2014) M Y Park et al. Mucosal Immunology
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11)
- (2014) Wei Qiu et al. BMC STRUCTURAL BIOLOGY
- Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors
- (2014) By Zhao et al. Journal for ImmunoTherapy of Cancer
- Evaluation of molecular model-based discovery of ecto-5′-nucleotidase inhibitors on the basis of X-ray structures
- (2013) Norbert Furtmann et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment
- (2013) F. Mussai et al. BLOOD
- Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
- (2013) J. A. Dubovsky et al. BLOOD
- Cellular and molecular mechanisms in cancer immune escape: a comprehensive review
- (2013) Alka Bhatia et al. Expert Review of Clinical Immunology
- Adenosine A2A Receptor as a Drug Discovery Target
- (2013) Manuel de Lera Ruiz et al. JOURNAL OF MEDICINAL CHEMISTRY
- Adenosine—a physiological or pathophysiological agent?
- (2013) Bertil B. Fredholm JOURNAL OF MOLECULAR MEDICINE-JMM
- Role of inositol phospholipid signaling in natural killer cell biology
- (2013) Matthew Gumbleton et al. Frontiers in Immunology
- TGF-β signalling and its role in cancer progression and metastasis
- (2012) Yvette Drabsch et al. CANCER AND METASTASIS REVIEWS
- Small molecule tools for functional interrogation of protein tyrosine phosphatases
- (2012) Rongjun He et al. FEBS Journal
- Modulation of T-cell function by type I interferon
- (2012) David F Tough IMMUNOLOGY AND CELL BIOLOGY
- Model-driven experimental analysis of the function of SHP-2 in IL-6-induced Jak/STAT signaling
- (2012) Anna Dittrich et al. Molecular BioSystems
- Unknown
- (2012) Gwenny Fuhler et al. MOLECULAR MEDICINE
- TGF-β signaling to T cells inhibits autoimmunity during lymphopenia-driven proliferation
- (2012) Nu Zhang et al. NATURE IMMUNOLOGY
- Adenosine and its receptors as therapeutic targets: An overview
- (2012) Sakshi Sachdeva et al. SAUDI PHARMACEUTICAL JOURNAL
- VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC
- (2011) H. Lu et al. CLINICAL CANCER RESEARCH
- CD39 Expression on T Lymphocytes Correlates With Severity of Disease in Patients With Chronic Lymphocytic Leukemia
- (2011) Dianne Pulte et al. Clinical Lymphoma Myeloma & Leukemia
- Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer
- (2011) Primo N. Lara et al. JOURNAL OF CLINICAL ONCOLOGY
- Non–lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatasePtpn11(Shp2) on malignant transformation of hematopoietic cells
- (2011) Dan Xu et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Impact of CD39 and purinergic signalling on the growth and metastasis of colorectal cancer
- (2011) Beat M. Künzli et al. Purinergic Signalling
- Vaccine adjuvant activity of 3M-052: An imidazoquinoline designed for local activity without systemic cytokine induction
- (2011) Dmitri Smirnov et al. VACCINE
- Inhibition of cellular Shp2 activity by a methyl ester analog of SPI-112
- (2010) Liwei Chen et al. BIOCHEMICAL PHARMACOLOGY
- Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13
- (2010) S. L. Highfill et al. BLOOD
- Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers
- (2010) Melissa A. Geller et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The Src, Syk, and Tec family kinases: Distinct types of molecular switches
- (2010) J. Michael Bradshaw CELLULAR SIGNALLING
- CD39/ENTPD1 Expression by CD4+Foxp3+ Regulatory T Cells Promotes Hepatic Metastatic Tumor Growth in Mice
- (2010) Xiaofeng Sun et al. GASTROENTEROLOGY
- Intracellular Toll-like Receptors
- (2010) Amanda L. Blasius et al. IMMUNITY
- SHIP1 Inhibition Increases Immunoregulatory Capacity and Triggers Apoptosis of Hematopoietic Cancer Cells
- (2010) R. Brooks et al. JOURNAL OF IMMUNOLOGY
- Development of Potent and Selective Inhibitors ofecto-5′-Nucleotidase Based on an Anthraquinone Scaffold
- (2010) Younis Baqi et al. JOURNAL OF MEDICINAL CHEMISTRY
- Salicylic Acid Based Small Molecule Inhibitor for the Oncogenic Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2)
- (2010) Xian Zhang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Toll-like receptors and innate immunity
- (2009) Himanshu Kumar et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Discovery and functional characterization of a novel small molecule inhibitor of the intracellular phosphatase, SHIP2
- (2009) A Suwa et al. BRITISH JOURNAL OF PHARMACOLOGY
- L-Arginine deprivation impairs Leishmania major-specific T-cell responses
- (2009) Markus Munder et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- The A2B Adenosine Receptor Impairs the Maturation and Immunogenicity of Dendritic Cells
- (2009) J. M. Wilson et al. JOURNAL OF IMMUNOLOGY
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade
- (2008) Gennady G. Yegutkin BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Inhibition of SHP2 leads to mesenchymal to epithelial transition in breast cancer cells
- (2008) X-D Zhou et al. CELL DEATH AND DIFFERENTIATION
- Inhibitors of Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (Shp2) Based on Oxindole Scaffolds
- (2008) Harshani R. Lawrence et al. JOURNAL OF MEDICINAL CHEMISTRY
- STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling
- (2008) Hiroki Ishikawa et al. NATURE
- The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
- (2008) Xin Yu et al. NATURE IMMUNOLOGY
- Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors
- (2008) D Miyamoto et al. ONCOGENE
- Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking
- (2008) K. Hellmuth et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2
- (2008) E. Lazar-Molnar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Role for SHIP in Stem Cell Biology and Transplantation
- (2008) William Kerr Current Stem Cell Research & Therapy
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started